Abstract:Adenosine A1/A2A receptors (A1R/A2AR) represent targets in nondopaminergic treatment of motor disorders such as Parkinson's disease (PD). As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve comprehensive PD therapies simultaneously addressing comorbid symptoms such as sleep disruption. Recognizing the wake-promoting capacity of histamine H3 receptor (H3R) antagonists in combination with the "caffeine-like effects" of A1R/A2AR antagonists, we designed A1R/A2AR/H3R MTLs, where a piperidino-/pyrrolidino(propyloxy)phenyl H3R pharmacophore was introduced with overlap into an adenosine antagonist arylindenopyrimidine core. These MTLs showed distinct receptor binding profiles with overall nanomolar H3R affinities (Ki < 55 nM). Compound 4 (ST-2001, Ki (A1R) = 11.5 nM, Ki (A2AR) = 7.25 nM) and 12 (ST-1992, Ki (A1R) = 11.2 nM, Ki (A2AR) = 4.01 nM) were evaluated in vivo. l-DOPA-induced dyskinesia was improved after administration of compound 4 (1 mg kg–1, i.p. rats). Compound 12 (2 mg kg–1, p.o. mice) increased wakefulness representing novel pharmacological tools for PD therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00914?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00914</a>.Spectroscopic and analytical data; general LC–MS analytics; general synthesis, fluorescence characterization of compound 12 (ST-1992); drug-likeness of synthetized MTLs 4 (ST-2001) and 12 (ST-1992); cell viability of human neuroblastoma cells treated with MTLs 2, 4 (ST-2001) , and 6; in vitro radioligand binding experiments for compounds 4 (ST-2001) and 12 (ST-1992); in vivo studies of compound 4 (ST-2001); additional in vivo evaluation of compound 12 (ST-1992); and experimental part with references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_002.csv">CSV</a>)Modeling structure of A2AR with preladenant (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_003.pdb">PDB</a>)Modeling structure of A2AR with ST-1992 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00914/suppl_file/jm0c00914_si_004.pdb">PDB</a>)This article has not yet been cited by other publications.

A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors

Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development

Progress in the pursuit of therapeutic adenosine receptor antagonists

International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update

Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives

Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands

Allosteric Modulation of Adenosine A2A Receptors as a New Therapeutic Avenue

A2B adenosine receptor signaling and regulation

Discovery of Highly Potent Adenosine A1 Receptor Agonists: Targeting Positron Emission Tomography Probes.

Medicinal chemistry of adenosine A3 receptor ligands

Machine Learning for Discovery of New ADORA Modulators

Adenosine A2A receptors in Parkinson’s disease treatment

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

Adenosine A 2A R/A 1 R Antagonists Enabling Additional H 3 R Antagonism for the Treatment of Parkinson’s Disease

Preclinical Evaluation of the First Adenosine A1 Receptor Partial Agonist Radioligand for Positron Emission Tomography Imaging

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity

Adenosine antagonists as potential therapeutic agents

In Vivo Positron Emission Tomography Imaging of Adenosine A2A Receptors

Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors